Literature DB >> 23292818

Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis.

Aaliya Yaqub1, Lorinda Chung.   

Abstract

Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by vasculopathy and excessive collagen production leading to fibrosis of the skin and internal organs. SSc patients are at risk of developing pulmonary hypertension (PH), a debilitating, progressive condition of the pulmonary vasculature that leads to right heart failure and death. This review is an updated summary of the epidemiology and risk factors for PH in SSc. We describe the current literature examining the incidence, prevalence, and demographic and clinical risk factors associated with PH in SSc. We also discuss classical and novel autoantibodies and potential biomarkers that may be helpful in the assessment of risk and prognosis of PH in SSc patients. The ultimate objective in understanding the risk of developing PH in SSc is early diagnosis and early initiation of appropriate therapy with the hope for improved outcomes for patients with SSc-PH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23292818     DOI: 10.1007/s11926-012-0302-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  46 in total

Review 1.  Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?

Authors:  Dermot S O'Callaghan; Peter Dorfmuller; Xavier Jaïs; Luc Mouthon; Olivier Sitbon; Gérald Simonneau; Marc Humbert; David Montani
Journal:  Presse Med       Date:  2011-01-05       Impact factor: 1.228

2.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

Review 3.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

Review 4.  Geoepidemiology of systemic sclerosis.

Authors:  Brigitte Ranque; Luc Mouthon
Journal:  Autoimmun Rev       Date:  2009-11-10       Impact factor: 9.754

5.  Isolated pulmonary hypertension in scleroderma.

Authors:  S R Cox; J G Walker; M Coleman; M Rischmueller; S Proudman; M D Smith; M J Ahern; P J Roberts-Thomson
Journal:  Intern Med J       Date:  2005-01       Impact factor: 2.048

Review 6.  Scleroderma epidemiology.

Authors:  Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

7.  Age and risk of pulmonary arterial hypertension in scleroderma.

Authors:  Lionel Schachna; Fredrick M Wigley; Betty Chang; Barbara White; Robert A Wise; Allan C Gelber
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

Review 8.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

9.  Anti-U3 RNP autoantibodies in systemic sclerosis.

Authors:  Rohit Aggarwal; Mary Lucas; Noreen Fertig; Chester V Oddis; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2009-04

10.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  11 in total

1.  Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?

Authors:  Bihter Senturk; Bahri Akdeniz; Mehmet Birhan Yilmaz; Buse Ozcan Kahraman; Burak Acar; Sadettin Uslu; Merih Birlik
Journal:  Clin Rheumatol       Date:  2019-05-26       Impact factor: 2.980

2.  Echocardiographic assessment of regional right ventricular systolic function using two-dimensional strain echocardiography and evaluation of the predictive ability of longitudinal 2D-strain imaging for pulmonary arterial hypertension in systemic sclerosis patients.

Authors:  Vedat Hekimsoy; Ergun Barıs Kaya; Ali Akdogan; Levent Sahiner; Banu Evranos; Ugur Canpolat; Kudret Aytemir; Necla Özer; Lale Tokgozoglu
Journal:  Int J Cardiovasc Imaging       Date:  2018-01-10       Impact factor: 2.357

3.  Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.

Authors:  Monique Hinchcliff; Saira Khanna; Vivien M Hsu; Jungwha Lee; Orit Almagor; Rowland W Chang; Virginia Steen; Lorinda Chung
Journal:  Semin Arthritis Rheum       Date:  2015-06-19       Impact factor: 5.532

Review 4.  An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature.

Authors:  Sneha M Sundaram; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2018-02-27       Impact factor: 4.592

5.  Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension.

Authors:  Jin Qian; Wen Tian; Xinguo Jiang; Rasa Tamosiuniene; Yon K Sung; Eric M Shuffle; Allen B Tu; Antonia Valenzuela; Shirley Jiang; Roham T Zamanian; David F Fiorentino; Norbert F Voelkel; Marc Peters-Golden; Kurt R Stenmark; Lorinda Chung; Marlene Rabinovitch; Mark R Nicolls
Journal:  Hypertension       Date:  2015-10-05       Impact factor: 10.190

6.  Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study.

Authors:  Silje Reiseter; Øyvind Molberg; Ragnar Gunnarsson; May Brit Lund; Trond Mogens Aalokken; Pål Aukrust; Thor Ueland; Torhild Garen; Cathrine Brunborg; Annika Michelsen; Aurelija Abraityte; Anna-Maria Hoffmann-Vold
Journal:  Arthritis Res Ther       Date:  2015-08-28       Impact factor: 5.156

7.  Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme.

Authors:  Kathleen Morrisroe; Wendy Stevens; Joanne Sahhar; Candice Rabusa; Mandana Nikpour; Susanna Proudman
Journal:  Arthritis Res Ther       Date:  2017-03-07       Impact factor: 5.156

8.  Nearest Consensus Clustering Classification to Identify Subclasses and Predict Disease.

Authors:  Awad A Alyousef; Svetlana Nihtyanova; Chris Denton; Pietro Bosoni; Riccardo Bellazzi; Allan Tucker
Journal:  J Healthc Inform Res       Date:  2018-07-30

9.  Pulmonary hypertension surveillance: United States, 2001 to 2010.

Authors:  Mary G George; Linda J Schieb; Carma Ayala; Anjali Talwalkar; Shaleah Levant
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

10.  Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study.

Authors:  Kathleen Morrisroe; Molla Huq; Wendy Stevens; Candice Rabusa; Susanna M Proudman; Mandana Nikpour
Journal:  BMC Pulm Med       Date:  2016-09-27       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.